PharmAla Biotech Advances MDMA Manufacturing and Novel ALA-002 Development for Clinical Trials
核心洞察
PharmAla Biotech (搜索) has completed release testing of its first Australian-manufactured LaNeo MDMA (搜索) 40mg capsules and delivered them to the Orygen Institute (搜索) for a Phase 3 trial examining social anxiety (搜索) in autistic youth (搜索).
The company has contracted with a UK-based CDMO to manufacture its novel ALA-002 drug substance, marking the first new Active Pharmaceutical Ingredient development since 2022.
PharmAla plans to initiate Phase 2a/2b clinical trials for ALA-002 in Social Anxiety Disorder (搜索) in 2026, while expanding its production schedule to include 20mg capsules and ALA-002 formulations.
PharmAla Biotech (搜索) Holdings Inc. has achieved significant manufacturing milestones for its MDMA-based therapeutics, completing release testing of its first Australian-made LaNeo MDMA (搜索) capsules and securing manufacturing partnerships for its novel drug candidate ALA-002. The biotechnology company, which focuses on MDXX class molecules, is positioning itself for expanded clinical trial activities in 2026.
Australian Manufacturing Milestone
The company successfully completed release testing of its first batch of Australian-manufactured LaNeo MDMA (搜索) 40mg capsules, produced in partnership with Cortexa (搜索). "PharmAla is pleased to have completed this first batch of material of Australian-made materials in partnership with our colleagues at Cortexa," said Farnoud Kazemzadeh, COO of PharmAla Biotech (搜索). "This material will continue to drive progress in the Australian market, as well as our ongoing operations globally."
The Australian-made capsules have been delivered to the Orygen Institute (搜索) to support their Phase 3 trial examining social anxiety (搜索) in autistic youth (搜索). This shipment represents the final delivery under PharmAla's contract with Orygen, concluding the company's involvement in this specific clinical program.
Novel Drug Development Progress
PharmAla's wholly-owned subsidiary, PharmAla Biotech (搜索) Australia, has contracted with a UK-based Contract Development and Manufacturing Organization (CDMO) to manufacture ALA-002 drug substance. The company conducted a global Request for Proposal (RFP) search to identify the optimal manufacturing partner for process development and production of ALA-002 drug product components.
"This is an important and necessary step to us executing our ALA-002 Phase 2 clinical trial in 2026, and the first time since 2022 that PharmAla will be developing a wholly new Active Pharmaceutical Ingredient for human use," said Nick Kadysh, Founding CEO of PharmAla Biotech (搜索).
ALA-002 represents PharmAla's patented, novel, non-racemic MDMA formulation. The company has announced plans to initiate Phase 2a/2b clinical research investigating ALA-002 for Social Anxiety Disorder (搜索) in 2026. Due to the controlled substance nature of ALA-002, PharmAla is not publicly disclosing the CDMO's identity at their request.
Expanded Production Plans
Looking ahead to 2026, PharmAla anticipates an active production schedule that includes the development and release of 20mg LaNeo capsules and the manufacture and encapsulation of the first run of ALA-002 capsules. This expansion reflects the company's growing manufacturing capabilities and clinical pipeline advancement.
Clinical Supply Deliveries
The company has also completed one of two contracted shipments of LaNeo MDMA (搜索) to the Parsons Research Center for Psychedelic Healing at Mount Sinai Hospital. This material is scheduled for use in clinical research, further demonstrating PharmAla's role as a supplier of clinical-grade MDMA for therapeutic research.
PharmAla positions itself as the only company currently providing clinical-grade MDMA for patient treatments outside of clinical trials. The company operates under a "regulatory first" principle, emphasizing the importance of maintaining excellent relationships with regulatory authorities for success in the psychedelics industry.